HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.04140609v1 4/10/1670    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Rovin, B. H. Articles by Birmingham, D. J. PubMed PubMed Citation Articles by Rovin, B. H. Articles by Birmingham, D. J.

Can We Personalize Treatment for Kidney Diseases?

Division of Nephrology, Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio

Correspondence: Dr. Brad H. Rovin, Division of Nephrology, Ohio State University College of Medicine, 395 W. 12th Avenue, Ground Floor, Columbus, OH 43210. Phone: 614-293-4997; Fax: 614-293-3073; E-mail: rovin.1{at}osu.edu

The idea of individualizing therapies to obtain optimal clinical results is not new but has only recently been applied to kidney diseases. Nonetheless, kidney disorders present a variety of opportunities to personalize medicine. Here, the heterogeneity of kidney disorders is reviewed to provide a rationale for pursuing personalized medicine. Data on adjusting therapy on the basis of pharmacogenetics/genomics and pharmacodynamics are summarized to demonstrate where the field is, and biomarker studies that reflect the future of personalized medicine are discussed. The goal of this review is to demonstrate that we can personalize therapy for kidney diseases but that considerable investment in new research will be required for personalized medicine to be routinely used in nephrology clinics.